High demand, high prices, and emerging new uses are likely to put a significant burden on Medicare spending and Part D plan cost premiums.
Physicians should avoid prescribing to: Patients with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) Individuals with severe gastrointestinal disorders (such as gastroparesis) Patients with a known hypersensitivity to GLP-1 or GIP receptor agonists Pregnant or breastfeeding women, unless deemed necessary by a healthcare provider Potential Side Effects Like any medication, this may cause side effects, though most are mild and transient. Common Side Effects (Usually Improve Over Time) Mild nausea (most common, usually decreases after the first few weeks) Vomiting or diarrhea in some cases, especially during dose escalation Constipation or bloating as digestion slows Mild fatigue or headaches as the body adjusts Less Common But Serious Side Effects Severe gastrointestinal distress (persistent nausea, vomiting, or diarrhea requiring discontinuation) Pancreatitis (rare) Monitor for severe abdominal pain Hypoglycemia (rare in non-diabetics) May occur if combined with other insulin-stimulating agents Allergic reactions (very rare) Swelling, rash, or difficulty breathing Physicians should titrate doses gradually to minimize side effects and improve patient tolerance
It stimulates the release of neurotransmitters in your brain, specifically norepinephrine, that signal your body to enter "fight or flight" mode, which naturally reduces hunger signals
They're motivated
As off-label use continues to expand, particularly among patients with obesity or insulin resistance, our findings suggest GLP-1based therapies may warrant consideration as an adjunct to insulin in carefully selected patients. Advertisement Advertisement New service for patients with diabetes will make annual screening more convenient Association revises criteria for the diagnosis and resolution of severe conditions What to consider in the management of euglycemic DKA Less than 50% of patients with diabetes get appropriate ophthalmic screening through primary care referrals Familiarity will enhance its accessibility for patients with diabetes New study counters earlier findings linking drugs with eye disease Study highlights the value of quantitative ultra-widefield angiography Longevity in healthcare, personal experiences may provide caregivers with false sense of confidence
Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030) 5.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR) 5.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors 5.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment 5.5 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics 5.6 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel 5.6.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview 5.6.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR) 5.6.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR) 5.6.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR) 5.7 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration 5.7.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview 5.7.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR) 5.7.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR) 5.8 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use 5.8.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview 5.8.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR) 5.8.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR) 5.8.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR) 5.9 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country 5.9.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview 5.9.2 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR) 5.9.2.1 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel 5.9.2.2 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration 5.9.2.3 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use 5.9.3 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR) 5.9.3.1 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use 5.9.3.2 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration 5.9.3.3 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel 5.9.4 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR) 5.9.4.1 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use 5.9.4.2 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration 5.9.4.3 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel 6
